Search for content, post, videos

Scandion Oncology appoints new CFO

Johnny Stilou

Scandion Oncology has announced that Johnny Stilou has been appointed as the company’s new CFO, and joins the company, effective no later than August 1, 2021.

He has a long experience from both Danish and international listed companies – most recently Nuevolution AB and Amgen Inc, states the company in a press release. Johnny Stilou succeeds Carit Jacques Andersen, who wishes to pursue a career outside Scandion Oncology.

“I am very pleased that we have attracted Johnny Stilou to Scandion Oncology. We are evolving the company and we need a focused capital market strategy in order to fund our operations optimally and secure a strong investor base. Johnny will bring a steady hand on the steering wheel with all the attributes required for a successful implementation of our capital market strategy,” says Bo Rode Hansen.


CFO of Nuevolution

Johnny Stilou’s financial background includes positions as CFO of Nuevolution (acquired by Amgen Inc.) and EVP & CFO of Veloxis Pharmaceuticals. Johnny has a successful track record of leading finance organizations in listed main market companies at Nasdaq as well as in-depth experience with capital markets and corporate finance, the company states.